Article
Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
BMC cancer - 11 Jan 2021
Park Sojung, Lee Sung Yong, Kim Dojin, Sim Yun Su, Ryu Jeong-Seon, Choi Juwhan, Lee Su Hwan, Ryu Yon Ju, Lee Jin Hwa, Chang Jung Hyun
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer predict sensitivity to EGFR tyrosine kinase inhibitors (TKIs). EGFR mutation types are associated with efficacy of EGFR TKIs. We investigated the clinical outcomes of afatinib, erlotinib, and gefitinib according to EGFR mutation type in patients with lung adenocarcinoma. METHODS: Between May 2010 and December 2018, we...
Topics
- Adenocarcinoma of Lung
- Aged
- Biomarkers, Tumor
- Carcinoma, Non-Small-Cell Lung
- ErbB Receptors
- Female
- Follow-Up Studies
- Humans
- Lung Neoplasms
- Male
- Mutation
- Prognosis
- Protein Kinase Inhibitors